GANYMED PHARMACEUTICALS
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
GANYMED PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2001-01-01
Address:
Mainz, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.ganymed.ag
Total Employee:
11+
Status:
Closed
Contact:
49 6131 1440 100
Email Addresses:
[email protected]
Total Funding:
212.7 M USD
Technology used in webpage:
MarkMonitor DNS 040 Hosting
Current Advisors List
Current Employees Featured
Founder
Investors List
Future Capital
Future Capital investment in Series E - Ganymed Pharmaceuticals
MIG
MIG investment in Series E - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series E - Ganymed Pharmaceuticals
FCPB
FCPB investment in Series E - Ganymed Pharmaceuticals
Future Capital
Future Capital investment in Series D - Ganymed Pharmaceuticals
MIG
MIG investment in Series D - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series D - Ganymed Pharmaceuticals
ATS Beteiligungsverwaltung
ATS Beteiligungsverwaltung investment in Series C - Ganymed Pharmaceuticals
VI Partners
VI Partners investment in Series C - Ganymed Pharmaceuticals
Ingro Finanz AG
Ingro Finanz AG investment in Series C - Ganymed Pharmaceuticals
